UNSPSC 51314365: Dextromethorphan/ipecac/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314365 Dextromethorphan/ipecac/potassium guaiacolsulfonate/promethazine is a Commodity code, but the recent state and local solicitations tagged under it do not align with the code's nominal pharmaceutical ingredients—instead, they reflect active procurement of emergency medical countermeasures, generic multi-source pharmaceuticals, and pharmacy benefit program solutions. State and local health departments, HHS commissions, and cooperative purchasing alliances are soliciting naloxone systems, generic pharmaceutical inventories, and direct-to-manufacturer prescription programs to support community health initiatives, employee health plans, and multi-jurisdictional pharmacy networks. The issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Vendors are typically manufacturers, wholesalers, or pharmacy benefit intermediaries with FDA-compliant production and supply-chain security certifications.

Geographic activity spans Florida, Texas, Minnesota, Oregon, and participating MMCAP jurisdictions. Recent representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs for self-insured employee health plans; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. Vendors must comply with cGMP, DSCSA, FDA expiration and shelf-life standards, E-Verify employment verification, and maintain commercial general liability insurance at $5,000,000 per occurrence. Cooperative purchasing arrangements and multi-award structures are common; pricing is typically fixed or net-based with competitive evaluation weighted toward price competitiveness (75 percent in the MMCAP procurement).